Abstract
BackgroundLack of reliable and valid measures of disease activity and clinical response in patients with CTD-ILD makes clinical trial design difficult. From a multi-tiered investigation to develop consensus on provisional...
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have